Single-stranded HDR templates with truncated Cas12a binding sequences improve knock-in efficiencies in primary human T cells
Preprint
Abstract
Non-viral gene editing via CRISPR-Cas12a offers an alternative to Cas9-based methods, providing better targeting of AT-rich regions, simplified guide RNA manufacturing, and high specificity. However, the efficacy of editing outcomes is subject to various factors, with template format playing a crucial role. Currently, the predominant non-viral template format for inducing homology-directed repair (HDR) after nuclease-induced DNA breaks is double-stranded DNA (dsDNA), which is toxic when transfected at high doses. Previous studies have demonstrated that using single-stranded DNA (ssDNA) with flanking double-stranded Cas-target-sequences (CTS) as a repair template for Cas9-mediated gene editing can mitigate this toxicity and increase knock-in efficiency. Here, we investigate CTS design for AsCas12a Ultra by exploring PAM orientation and binding requirements of the Cas12a-crRNA complex. Additionally, we rule out in vitro ssDNase activity of AsCas12a Ultra under cell-physiological Mg 2+ conditions. Finally, we showcase the advantage of using ssDNA with double-stranded CTS end modifications (ssCTS) at high doses for delivering clinically relevant transgenes of varying sizes into three T-cell receptor-CD3 complex genes ( TRAC , CD3 ζ , CD3 ε), achieving up to 90% knock-in rates for a 0.8kb insert at the CD3 ε locus. Overall, AsCas12a Ultra and ssCTS donors represent a platform for highly efficient knock-in in primary human T cells with minimal toxicity.Keywords
All Related Versions
- Published version: Molecular Therapy Nucleic Acids, 36 (2), 102568.
This publication has 59 references indexed in Scilit:
- Miniaturized CAR knocked onto CD3ε extends TCR function with CAR specificity under control of endogenous TCR signaling cascadeJournal of Immunological Methods, 2024
- Engineering T cell receptor fusion proteins using nonviral CRISPR/Cas9 genome editing for cancer immunotherapyBioengineering & Translational Medicine, 2023
- Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cellsMolecular Therapy - Methods & Clinical Development, 2022
- Cas9‐Cleavage Sequences in Size‐Reduced Plasmids Enhance Nonviral Genome Targeting of CARs in Primary Human T CellsSmall Methods, 2021
- CRISPR-Cas12a Possesses Unconventional DNase Activity that Can Be Inactivated by Synthetic OligonucleotidesMolecular Therapy Nucleic Acids, 2020
- Kinetic Basis for DNA Target Specificity of CRISPR-Cas12aMolecular Cell, 2018
- Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejectionNature, 2017
- Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cellsNature Biotechnology, 2016
- Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cellsNature Biotechnology, 2016
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas SystemCell, 2015